We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$2B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
-13.75%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$142M
(-12%)
Cap. Flow
+$82.3M
Cap. Flow
% of AUM
8.03%
Top 10 Holdings %
Top 10 Hldgs %
68.99%
Holding
83
New
24
Increased
8
Reduced
9
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Design Therapeutics
DSGN
|
+$92.2M |
| 2 |
Instil Bio
TIL
|
+$47.4M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$34.3M |
| 4 |
Dyne Therapeutics
DYN
|
+$31M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TG Therapeutics
TGTX
|
+$44.2M |
| 2 |
Keros Therapeutics
KROS
|
+$31.7M |
| 3 |
Nkarta
NKTX
|
+$20.1M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$17.2M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$17.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.46% |
| 2 | Financials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$280M
| $233M | 22.72% |
3,156,981
| – | – |
|
2
Olema Pharmaceuticals
OLMA
$1.07B
| $124M | 12.12% |
3,743,875
| – | – |
|
|
3
Design Therapeutics
DSGN
$748M
| $81.7M | 7.97% |
+2,732,501
| New | +$92.2M |
|
|
4
Dyne Therapeutics
DYN
$4.19B
| $49.8M | 4.86% |
3,204,392
+1,600,000
| +100% | +$31M |
|
|
5
Instil Bio
TIL
$48.5M
| $46.3M | 4.52% |
+92,343
| New | +$47.4M |
|
|
6
Nkarta
NKTX
$168M
| $41.5M | 4.05% |
1,260,877
-421,301
| -25% | -$20.1M |
|
|
FMTX
7
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $39.5M | 3.86% |
1,410,000
+10,000
| +0.7% | +$361K |
|
|
8
Edgewise Therapeutics
EWTX
$4.45B
| $34.3M | 3.35% |
+1,056,812
| New | +$34.3M |
|
|
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $29.1M | 2.84% |
934,602
+365,000
| +64% | +$12.7M |
|
|
RPTX
10
DELISTED
Repare Therapeutics
RPTX
| $27.6M | 2.7% |
900,000
+223,106
| +33% | +$7.58M |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $24M | 2.35% |
200,000
+80,000
| +67% | +$9.06M |
|
|
BCYC
12
Bicycle Therapeutics
BCYC
$275M
| $23.9M | 2.33% |
+800,000
| New | +$20.6M |
|
|
LONA
13
LeonaBio Inc
LONA
$69.6M
| $18.6M | 1.82% |
101,081
+6,294
| +7% | +$1.39M |
|
14
BioXcel Therapeutics
BTAI
$26.4M
| $17.3M | 1.68% |
25,000
-1,875
| -7% | -$1.51M |
|
15
Cullinan Oncology
CGEM
$1.09B
| $17.2M | 1.68% |
+413,458
| New | +$16.8M |
|
16
Cytokinetics
CYTK
$10.9B
| $16.3M | 1.59% |
+700,000
| New | +$14.9M |
|
|
TPTX
17
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $13.2M | 1.29% |
+140,000
| New | +$16.6M |
|
18
Cogent Biosciences
COGT
$6.96B
| $12.5M | 1.22% |
1,420,500
-500,000
| -26% | -$4.81M |
|
|
IMA
19
ImageneBio Inc
IMA
$63.1M
| $11.9M | 1.16% |
+34,988
| New | +$12M |
|
20
Aligos Therapeutics
ALGS
$26.3M
| $10.8M | 1.06% |
19,062
-5,200
| -21% | -$3.46M |
|
21
Kymera Therapeutics
KYMR
$9.18B
| $10.1M | 0.99% |
260,920
+150,000
| +135% | +$9.03M |
|
|
VINC
22
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $9.26M | 0.9% |
+24,000
| New | +$9.68M |
|
|
CMPS
23
Compass Pathways
CMPS
$1.54B
| $9.21M | 0.9% |
250,000
-50,000
| -17% | -$2.19M |
|
24
Viridian Therapeutics
VRDN
$2.18B
| $9.19M | 0.9% |
550,000
| – | – |
|
|
ASLN
25
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $7.71M | 0.75% |
+57,500
| New | +$7.29M |
|
Similar funds
MYAM
RCM
LBC
C
CAM
BGM
SC
AF
Logos Global Management's Q1 2021 Portfolio in Review
As of Q1 2021, Logos Global Management held 83 positions worth $1.02B, down 12% from $1.17B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Logos Global Management deployed $82.3M of net new capital in Q1 2021, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Design Therapeutics: 2,732,501 shares worth $81.7M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Nkarta, an estimated $20.1M trimmed.
- Logos Global Management's largest Q1 2021 buy was Design Therapeutics: 2,732,501 shares worth $81.7M.
- Logos Global Management added most to Dyne Therapeutics in Q1 2021, an estimated $31M increase.
- Logos Global Management's biggest Q1 2021 reduction was Nkarta, cutting an estimated $20.1M.
- Logos Global Management fully exited TG Therapeutics in Q1 2021, selling an estimated $44.2M.
- Logos Global Management's ten largest holdings make up 69% of its $1.02B portfolio in Q1 2021.
- Logos Global Management opened 24 new positions and closed 30 in Q1 2021.
- Logos Global Management's portfolio value fell 12% quarter-over-quarter to $1.02B.
Based on Logos Global Management's 13F filing for Q1 2021, filed 17 May 2021.